The effects of systemic immunomodulatory treatments on covid-19 outcomes in patients with atopic dermatitis: results from the global secure-ad registry

Journal of the European Academy of Dermatology and Venereology : JEADV(2022)

引用 2|浏览37
暂无评分
摘要
Overall, the risk of COVID-19 complications appears low in patients with AD, even when treated with systemic immunomodulatory agents. Dupilumab monotherapy was associated with lower hospitalization than other therapies. Combination systemic treatment, particularly combinations including systemic corticosteroids, was associated with the highest risk of severe COVID-19.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络